Abbvie Inc. is a global pharmaceutical company that focuses on discovering, developing, manufacturing, and selling a wide range of treatments. Its portfolio includes therapies for autoimmune diseases, various cancers, eye diseases, neurological disorders, and more. Notable products include Humira for autoimmune conditions, Skyrizi and Rinvoq for skin and joint diseases, and Imbruvica for blood cancers. AbbVie also offers products in aesthetics, women's health, and eye care. Founded in 2012 and based in North Chicago, Illinois, AbbVie collaborates with several biotech firms to advance its research in oncology and immunology.
AbbVie cleared its August record with a fresh 52-week high at $266.28, 0.12% above the prior peak, on the same day it announced FDA approval of JUVMO. A $470.9 billion pharma making new highs is a momentum signal income investors rarely get.
Sessions dumped a big pharma name and Alphabet on the same day, then filed within four days, an unusually fast turnaround that pins down the timing. Paired healthcare and megacap tech selling from a sitting House member is a signal to catch before the next leg of either trade.
Six names hit fresh 52-week highs this week: SentinelOne led at 6.14% above its prior peak, with Coca-Cola, Expedia, Airbnb, AbbVie and Pfizer all clearing old ceilings too.
AbbVie touched a new 52-week high at $265.97, clearing its July 29 peak. The $470 billion pharma has left its spring range near $200 behind.
Bank of America just raised price targets on two pharma giants facing patent cliffs, but its conviction level differs sharply between them, and the valuation gap may explain which one belongs in…
Johnson & Johnson's oncology and immunology pipeline is firing on multiple cylinders, but a collapsing blockbuster drug and mounting litigation costs threaten to cancel out every gain. Here is whether the bull…
Chasing the highest dividend yield is exactly how investors end up owning something that quietly eats their principal alive. A six-holding portfolio shows how a much lower yield can generate far more…
AbbVie and Johnson and Johnson both trade near 52-week highs and carry decades of dividend raises, but one faces a patent cliff and a leveraged balance sheet that could force retirees to…
With the third quarter closing out, income investors have a narrow window to lock in three cash-generative blue chips before Q3 earnings reset expectations. The shared hook: recession-resilient franchises, multi-decade dividend histories,…
Replacing a top-tier salary with dividends sounds like a portfolio problem, but the yield you chase could cost you far more than the shares you buy. The answer depends on a tradeoff…
A biopharma giant, a chip maker, a delivery network, a trash hauler, and an oncology powerhouse walk into the same portfolio for one reason, and it has nothing to do with chasing…
The capital required to replace a professional salary with investment income swings by more than $2 million depending on one decision, and most investors default to the wrong tier without realizing it.
SCHD's 0.06% expense ratio gets all the attention, but something that happened quietly in March may have cost dividend investors far more than a decade of fees combined.
Two portfolios generating identical dividend income can leave one investor thousands of dollars richer than the other, and the difference has nothing to do with yield. The culprit is hiding inside your…
A Roth IRA turns every dividend into a tax shield: qualified distributions in retirement escape federal income tax entirely, and reinvested payouts compound without a drag from Uncle Sam. That advantage is…
Your Medicare premium leaves your Social Security check before you ever see it, but the right dividend portfolio changes that equation permanently. The tricky part is knowing exactly how much capital your…
Building a retirement income sleeve around seven funds sounds like diversification, but the largest position in this blueprint has a quiet habit of inflating its own payout once a year without ever…
A $250,000 rollover sounds like a clean starting point until you realize yield alone is not the whole story, and only one name on this roster actually clears the current Treasury rate.…
AbbVie's flagship drug is bleeding revenue quarter after quarter, yet the company just handed shareholders another raise. Find out whether the cash machine holding this payout together can survive the patent reckoning…
Chris Lange 
